Disease modifying activity of HWA 486 in rat adjuvant-induced arthritis

Agents and Actions

Volumn 21, Issue 3-4, 1987, Pages 241-243

  Pasternak, R D ^a   Wadopian, N S ^a   Wright, R N ^a   Siminoff, P ^a   Gylys, J A ^a   Buyniski, J P ^a  

^a BRISTOL MYERS SQUIBB COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; CYCLOSPORIN; LEFLUNOMIDE;

ANIMAL EXPERIMENT; DELAYED HYPERSENSITIVITY; NONHUMAN; POLYARTHRITIS; RAT;

ANIMAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS; ARTHRITIS, EXPERIMENTAL; COMPARATIVE STUDY; CYCLOSPORINS; HYPERSENSITIVITY, DELAYED; IN VITRO; ISOXAZOLES; LYMPHOCYTE ACTIVATION; MALE; OXAZOLES; RATS; RATS, INBRED LEW;

EID: 0023553077     PISSN: 00654299     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/BF01966478     Document Type: Article

References (2)

1. Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity — I. Disease modifying action on adjuvant arthritis of the rat
2. Immunopharmacological profile of HWA 486, a novel isoxazol derivative — II. In vivo immunomodulating effects differ from those of cyclophosphamide, prednisolone or cyclosporin A